The invention provides an improved pan-TGF-á antibody for treatment of conditions that are mediated by TGF-á, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.